0001104659-23-020900.txt : 20230214
0001104659-23-020900.hdr.sgml : 20230214
20230214091448
ACCESSION NUMBER: 0001104659-23-020900
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230213
FILED AS OF DATE: 20230214
DATE AS OF CHANGE: 20230214
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duran Felipe
CENTRAL INDEX KEY: 0001964267
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35023
FILM NUMBER: 23623290
MAIL ADDRESS:
STREET 1: 8800 HSC PARKWAY
CITY: BRYAN
STATE: TX
ZIP: 77807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iBio, Inc.
CENTRAL INDEX KEY: 0001420720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 262797813
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 600 MADISON AVENUE, SUITE 1601
CITY: NEW YORK
STATE: NY
ZIP: 10022-1737
BUSINESS PHONE: 302 355-0650
MAIL ADDRESS:
STREET 1: 600 MADISON AVENUE, SUITE 1601
CITY: NEW YORK
STATE: NY
ZIP: 10022-1737
FORMER COMPANY:
FORMER CONFORMED NAME: iBioPharma, Inc.
DATE OF NAME CHANGE: 20080806
FORMER COMPANY:
FORMER CONFORMED NAME: InB:Biotechnologies, Inc.
DATE OF NAME CHANGE: 20071210
3
1
tm236684-1_3.xml
FORM 3
X0206
3
2023-02-13
0
0001420720
iBio, Inc.
IBIO
0001964267
Duran Felipe
C/O IBIO, INC., 8800 HSC PARKWAY
BRYAN
TX
77807
0
1
0
0
Interim CFO
Common Stock (RSU)
2133
D
Stock Option (Right to Buy)
32.25
2022-05-04
2031-05-04
Common Stock
2800
D
Stock Option (Right to Buy)
31.50
2022-08-23
2031-08-23
Common Stock
1000
D
Stock Option (Right to Buy)
7.00
2022-08-29
2031-08-29
Common Stock
12000
D
Consists of 2,133 shares of iBio, Inc. (the "Company") common stock, $0.001 par value per share (the "Common Stock") represented by 2,133 restricted stock units ("RSUs") granted under the Company's 2020 Omnibus Equity Incentive Plan, (the "2020 Plan"). Each RSU represents a contingent right to receive one share of Common Stock. These RSUs will vest in even increments on the first three anniversaries of grant, subject to the conditions of the Plan and grant agreement.
25% of options granted will vest one year following the grant date; and after one year following the grant date, 6.25% of the options granted will vest for each additional 3 months of employment, subject to the conditions of the Plan and grant agreement.
/s/ Felipe Duran
2023-02-14